Results for tag: "Graft Versus Host Disease Drug"

Graft Versus Host Disease (GVHD) is a type of immune disorder that occurs when transplanted donor cells attack the recipient's body. It is a common complication of bone marrow and stem cell transplants. Treatment for GVHD typically involves immunosuppressive drugs, such as corticosteroids, calcineurin inhibitors, and monoclonal antibodies. These drugs are used to reduce inflammation and suppress the immune system, allowing the body to accept the donor cells. The GVHD drug market is a rapidly growing segment of the immune disorder drug market. It is driven by the increasing prevalence of GVHD, as well as the development of new drugs and treatments. The market is expected to continue to grow in the coming years, as more treatments become available and the demand for GVHD drugs increases. Some of the major companies in the GVHD drug market include Novartis, Celgene, Gilead Sciences, and Bristol-Myers Squibb. These companies are involved in the development and marketing of GVHD drugs, as well as other immune disorder drugs. Show Less Read more